FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 9.01 Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
Approval of Amendments to Equity Compensation Plans to Permit a One-Time Stock Option Exchange Program
At our annual meeting of stockholders held on August 1, 2017, the stockholders of Fluidigm Corporation (the “Company”) approved amendments (the “Amendments”) to the Company’s 2011 Equity Incentive Plan, 2009 Equity Incentive Plan, 1999 Stock Option Plan and the DVS Sciences, Inc. 2010 Equity Incentive Plan to permit a one-time option exchange, which amendments had been previously approved by the Company’s board of directors, subject to stockholder approval. The Amendments became effective as of the date of such stockholder approval.
The material features of the Amendments are described in the section entitled “Proposal Number 5- Approval of Amendments to Our Equity Compensation Plans to Allow for a One-Time Stock Option Exchange Program” on pages 30 through 48 of the definitive proxy statement as filed with the Securities and Exchange Commission (“Commission”) on June 29, 2017 (the “2017 Proxy”), which pages are incorporated herein by reference. The foregoing description and the description incorporated by reference from our 2017 Proxy are qualified in their entirety by reference to the copy of the Amendments, as approved by the Company’s Board and stockholders, which are filed as Exhibit 10.2 to our Current Report on Form 8-K filed with the Commission on August 2, 2017.
Item 9.01 Other Events.
The information set forth in Item 9.01 is incorporated by reference in this Item 9.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| ExhibitNo. | Description |
| 10.1 | Amendments to the Fluidigm Corporation 2011 Equity Incentive Plan, 2009 Equity Incentive Plan, and 1999 Stock Option Plan and the DVS Sciences, Inc. 2010 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on August 2, 2017). |
About FLUIDIGM CORPORATION (NASDAQ:FLDM)
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
